Shanghai Henlius Biotech, Inc.

2696

CNE100003N76

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.55 CNY

Average target price

16.39 CNY

Spread / Average Target

+20.94%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI HENLIUS BIOTECH, INC.	+5.47%	1.01B
CSL LIMITED	-5.77%	84.57B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	39.93B
BIOGEN INC.	-26.37%	27.93B
UCB	+52.09%	24.21B
BIOMARIN PHARMACEUTICAL INC.	-6.59%	17.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.37%	13.93B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.45%	12.3B
INCYTE CORPORATION	-15.88%	11.84B
SWEDISH ORPHAN BIOVITRUM AB	-2.85%	7.91B

Biopharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:15 2024-04-18 am EDT			5-day change	1st Jan Change
14.66 ^HKD	+0.69%		-0.14%	+5.47%

Apr. 17	Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug	MT
Apr. 17	Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration	CI

Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug	Apr. 17	MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration	Apr. 17	CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints	Apr. 08	CI
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints	Apr. 05	MT
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints	Apr. 05	CI
Shanghai Henlius Biotech Turns to Profit in 2023	Mar. 22	MT
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug	Mar. 14	MT
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection	Mar. 14	CI
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials	Mar. 13	MT
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration	Mar. 12	CI
Shanghai Henlius Biotech Expects Record Full-Year Profit	Mar. 05	MT
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 04	CI
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration	Feb. 29	CI
Henlius Biotech Completes Phase 1 Clinical Study of Denosumab Biosimilar	Feb. 01	MT
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed	Feb. 01	CI
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	Jan. 10	CI
Henlius Biotech Renews Promotional Services Deal With Jiangsu Fosun Pharmaceutical Sales for the Marketing of Breast Cancer Drug	Jan. 02	MT
Indonesia Grants Marketing Approval to Henlius Biotech's Small-Cell Lung Cancer Treatment	Dec. 29	MT
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration	Dec. 27	CI
Henlius Biotech Doses First Subject in Phase 1 Trial of Ipilimumab Biosimilar	Dec. 13	MT
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)	Dec. 13	CI
China Accepts Henlius Application for New Indication of Cancer Drug	Dec. 12	MT
Shanghai Henlius Biotech, Inc. Announces the New Drug Application for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment Oflocally Advanced or Metastatic Non-Squamous Non-Smallcell Lung Cancer Has Been Accepted By the National Medical Products Administration	Dec. 12	CI